Indian Market Outlook – 30 October 2025

nifty sensex going down

Market overview

The Indian market witnessed a sharp pull-back on 30 October as major indices slipped on weak global cues and foreign investor outflows. The Nifty 50 closed below 25,900 and the Sensex fell by nearly 600 points. A rate-cut by the Federal Reserve met expectations, but its signal that this could be the final cut of the year unnerved investors and triggered profit-booking.

Top Indices

IndexCloseΔ (pts)Δ (%)
Nifty 50~25,877.85↓ ~176~-0.68%
Sensex~84,404.46↓ ~593~-0.70%
Nifty BankDeclinedWeak
Nifty Midcap 100MixedFlat to modest down
Nifty Smallcap 100MixedFlat to modest down

Sectoral Performance

SectorTone
PharmaWeak – among the worst
MetalsUnder-performed
ITWeakish
Banks / FinancialsModerately weak
FMCG / ConsumerMixed
Infrastructure / Capital GoodsMixed

Key Market Statistics

MetricReading
Market breadthNegative – more declines than advances
FII/FPI flowsNet outflows
DII flowsMild support but limited

Top Movers

  • Losers: Dr Reddy’s Laboratories plunged ~4% amid regulatory news; Pharma index led declines.
  • Laggards: Select metal and IT stocks bore the brunt of risk-off positioning.
  • Gainers: A few defensive large-caps held up relatively better amid sector rotation.

What Moved the Market

  • A widely-expected rate cut by the Federal Reserve was offset by guidance that future cuts may not follow soon, cooling risk appetite.
  • Foreign institutional investors were net sellers, adding pressure to domestic equities.
  • Technical triggers: Nifty slipping below the 26,000 zone triggered stop-losses and amplified booking.
  • Global trade/geo-political jitters also weighed, diminishing appetite for cyclicals.

Global Cues

The global market tone turned cautious: US equity futures were flat, Asia-Pacific markets saw mixed performance and Europe opened weaker. Commodity prices remained volatile, and currency/interest-rate differentials kept investors cautious about emerging-market exposure.

Stocks to Watch

  • Pharma names (e.g., Dr Reddy’s, Sun Pharma) – given recent weakness and potential regulatory risk.
  • Metals/capital-goods names – monitor for signs of recovery if global demand stabilises.
  • Select large banks/financials – key for overall market direction; look for reversal signs.
  • Defensive large-caps – for portfolio protection till risk appetite improves.

Corporate Updates

  • Regulatory news in the pharma sector spooked stocks and contributed to the weakness.
  • Some large-cap announcements remained muted; lack of strong fresh catalysts added to hesitation.

Technical View – Next Session

Nifty 50

  • Support: ~25,650 – 25,700 (gap and prior short-term lows)
  • Deeper support: ~25,500
  • Resistance: ~26,100 – 26,200 (recent highs)
  • A bounce back above ~26,100 could restore positive bias; failure to hold ~25,650 may shift market into consolidation or weak-trend territory.

Bank Nifty

  • Support: ~53,800 – 54,200
  • Resistance: ~55,500

Outlook for Tomorrow

The tone for the next session is cautiously negative to neutral. After a sharp pull-back, markets may open tentatively with an eye on global cues and domestic flows. Buying near supports could emerge, but upside is likely capped until fresh catalysts arrive. Expect the Nifty to trade in a range roughly between 25,650 – 26,200, unless there is an unexpected positive trigger.

Disclaimer

The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.